Every material Form 8-K Cooper Companies (The) has filed with the SEC since August 28, 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
CooperCompanies said Albert G. White III stepped down as President, Chief Executive Officer and director on October 27, 2026, and independent director Walter M. Rosebrough, Jr. was named interim Executive Chair. The press release said the company's recent performance has not met expectations, and the company reaffirmed its fiscal 2026 guidance. Shareholders face a leadership change while a permanent CEO is sought, and the board is changing composition with Shlomo Nachman joining in December 2026 and three directors not seeking reelection.
Albert G. White III resigned as President, CEO and director effective October 27, 2026, and will remain a strategic advisor through April 1, 2027.
Walter M. Rosebrough, Jr. was appointed interim Executive Chair effective immediately; a CEO Search Committee of Lawrence E. Kurzius, Cynthia L. Lucchese and Teresa S. Madden will oversee the CEO search.
Shlomo Nachman will join the board effective December 8, 2026; Barbara Carbone, Colleen E. Jay and Robert S. Weiss will not stand for reelection at the 2027 Annual Meeting.
The company reaffirmed its fiscal 2026 guidance provided on September 9, 2026.
CooperCompanies said its strategic review is complete and the Board unanimously decided to retain CooperSurgical, while also expanding its share repurchase authorization from $2 billion to $3 billion. The same day it reported fiscal third-quarter results with revenue up 1% and non-GAAP diluted EPS up 4%, though GAAP EPS was lifted by a $307.2 million tax benefit.
Q3 revenue $1.066 billion, up 1%; non-GAAP diluted EPS $1.15, up 4% from $1.10
GAAP diluted EPS $2.24 versus $0.49, driven by a $307.2 million discrete tax benefit from a U.K. tax examination
Buyback authorization raised from $2 billion to $3 billion; about $1.5 billion remains available after $339.1 million repurchased in the quarter
Fiscal Q4 2026 non-GAAP diluted EPS guidance of $1.05 to $1.09; fiscal 2026 guidance of $4.51 to $4.55
CooperCompanies reported fiscal second-quarter 2026 revenue of $1.082 billion, up 8%, and non-GAAP diluted EPS of $1.21, up 26%, while a $271.6 million net litigation charge tied to the December 2023 CooperSurgical embryo culture media recall produced a GAAP net loss of $77.9 million. The company said it has reached settlements covering over 95% of claimants and expects most payments to be made in fiscal 2026, and it updated its fiscal 2026 guidance.
Revenue of $1.082 billion, up 8% from a year earlier and up 5% organically
GAAP diluted EPS of $(0.40) versus $0.44 a year earlier; non-GAAP diluted EPS of $1.21 versus $0.96
$271.6 million net pre-tax litigation charge in SG&A: $324.1 million accrued liabilities less $52.5 million expected insurance recoveries
Fiscal 2026 guidance: total revenue of $4.285 to $4.321 billion and non-GAAP diluted EPS of $4.58 to $4.66
CooperCompanies approved expanding its board from nine to ten directors and appointed Paul Keel, currently President and CEO of Envista Holdings, to the new seat effective July 1, 2026. Keel will also join the Audit Committee on the same date, and the company says he is independent under Nasdaq standards.
Board size increases from nine to ten directors, effective July 1, 2026
Paul Keel has been CEO of Envista Holdings since 2024 and previously was CEO of Smiths Group from 2021 to 2024
Keel joins the Audit Committee effective July 1, 2026
Keel will receive director compensation consistent with other non-employee directors, per the February 24, 2026 proxy statement
CooperCompanies reported fiscal first-quarter 2026 revenue of $1.024 billion, up 6% from a year earlier and up 3% organically, with GAAP diluted EPS of $0.66 versus $0.52. The company also raised its fiscal 2026 non-GAAP EPS and free cash flow guidance, which matters to shareholders because it points to higher expected earnings and cash generation for the full year.
Q1 revenue of $1.024 billion, up 6% reported and 3% organic; CooperVision $695.1 million and CooperSurgical $329.0 million
GAAP diluted EPS of $0.66 versus $0.52; non-GAAP diluted EPS of $1.10 versus $0.92
Fiscal 2026 guidance: non-GAAP diluted EPS of $4.58 to $4.66, free cash flow of $600 million to $625 million, revenue of $4.306 billion to $4.346 billion
Repurchased $92.5 million of common stock in the quarter; $873.9 million of authorization remains
Cooper Companies amended its 2021 term loan and 2024 revolving credit agreement on February 3, 2026, with PNC Bank as administrative agent. The changes extend the maturity of $950 million of term loans to February 3, 2031, and remove the credit spread adjustment across the facilities.
$950 million of term loans now mature February 3, 2031; $550 million keeps its existing maturity date
Incremental term loan cap raised to the greater of $1.365 billion and 100% of consolidated EBITDA
Pricing can now be based on non-credit enhanced senior unsecured debt ratings or the existing net indebtedness to EBITDA ratio, at the company's option
The 2024 revolving credit agreement amendment conforms its terms to the 2021 loan changes, including removing the credit spread adjustment
CooperCompanies appointed Walter M. Rosebrough, Jr. as a director effective January 3, 2026, and joined Browning West, an investment partnership, in a letter agreement with customary standstill and voting commitments. The agreement also commits the company to nominate Mr. Rosebrough at its 2026 annual meeting, to search for one more independent director, and to limit the board to ten directors during the cooperation period.
Mr. Rosebrough joins the board and its Corporate Governance and Nominating Committee effective January 3, 2026, and will receive the same compensation as other non-management directors.
The company agreed to search for one additional independent director, subject to Browning West's approval, and to appoint that person no later than June 30, 2026.
The board agreed to give due and serious consideration to appointing Mr. Rosebrough as Chairman by the end of 2026, according to the press release.
The cooperation period runs until 30 days before the 2027 annual meeting stockholder nomination deadline.
Cooper Companies said its Chief Financial Officer, Brian G. Andrews, took on the role of principal accounting officer on December 9, 2025, succeeding Agostino Ricupati, who remains Senior Vice President, Tax. The filing states no change to Mr. Andrews' compensation and no related-party transactions, so the change is administrative and does not alter the company's financial outlook.
Brian G. Andrews, EVP, CFO and Treasurer, assumed principal accounting officer role on December 9, 2025.
Agostino Ricupati moved from principal accounting officer to Senior Vice President, Tax.
Mr. Andrews has been EVP since 2020 and CFO and Treasurer since 2018.
No change to Mr. Andrews' compensation was made in connection with the role.
CooperCompanies reported fiscal fourth-quarter revenue of $1,065.2 million, up 5%, and non-GAAP diluted EPS of $1.15, up 11%, while GAAP diluted EPS fell 27% to $0.43 after reorganization-related charges of about $89 million. The company also initiated fiscal 2026 guidance of non-GAAP diluted EPS of $4.45 to $4.60, and Chairman Robert S. Weiss said he will step down as Chairman effective January 2, 2026, with director Colleen E. Jay succeeding him.
Q4 revenue $1,065.2 million, up 5%; GAAP diluted EPS $0.43, down 27%; non-GAAP diluted EPS $1.15, up 11%
Fiscal 2026 guidance: total revenue $4,299 to $4,338 million; non-GAAP diluted EPS $4.45 to $4.60; free cash flow $575 to $625 million
Reorganization activity in Q4 resulted in about $89 million in cash and non-cash charges; company expects about $50 million in annual pre-tax savings beginning fiscal 2026
Robert S. Weiss resigns as Chairman effective January 2, 2026, remains a director; Colleen E. Jay appointed Chairman
CooperCompanies reported fiscal third-quarter 2025 results for the period ended July 31, 2025, with revenue up 6% to $1,060.3 million and non-GAAP diluted EPS up 15% to $1.10, while GAAP diluted EPS fell 6% to $0.49. The company raised its fiscal 2025 non-GAAP diluted EPS guidance to $4.08 to $4.12, and CEO Al White said revenues were below expectations and that the company expects improving revenue in the fourth quarter and fiscal 2026. For shareholders, the decline in GAAP earnings and charges tied to a CooperSurgical product line exit sit alongside the higher adjusted earnings outlook.
Revenue of $1,060.3 million, up 6% year over year and up 2% organically; CooperVision revenue was $718.4 million and CooperSurgical revenue was $341.9 million.
GAAP diluted EPS was $0.49, down from $0.52; non-GAAP diluted EPS was $1.10, up from $0.96.
Fiscal 2025 guidance: non-GAAP diluted EPS of $4.08 to $4.12 and total revenue of $4,076 million to $4,096 million.
Repurchased $52.1 million of common stock in the quarter, with $163.6 million of remaining program availability.
CooperCompanies reported fiscal second-quarter 2025 results for the period ended April 30, 2025, with revenue up 6% to $1,002.3 million and non-GAAP diluted EPS up 14% to $0.96. GAAP diluted EPS was $0.44, flat from a year earlier, and the company updated its fiscal 2025 guidance, though the filing does not show the prior guidance for comparison. The company also repurchased $40.6 million of common stock during the quarter.
Revenue of $1,002.3 million, up 6% from $942.6 million a year earlier, and up 7% organically.
GAAP diluted EPS of $0.44, flat year over year; non-GAAP diluted EPS of $0.96, up from $0.85.
Updated fiscal 2025 guidance: total revenue of $4,107 million to $4,146 million and non-GAAP diluted EPS of $4.05 to $4.11.
Repurchased $40.6 million of stock at an average price of $75.60; $215.8 million of authorization remains.
CooperCompanies (COO) said its board will grow from seven to eight directors effective May 1, 2025, and has appointed Barbara Carbone to fill the new seat as an independent director. She will also join the Audit Committee. The filing discloses no financial results or guidance, so the change is a governance update rather than a change in the company's operating outlook.
Board expands from seven to eight directors, effective May 1, 2025
Barbara Carbone appointed independent director, effective May 1, 2025, and to the Audit Committee
Carbone was a KPMG LLP partner from 1981 to 2019, including over 24 years as an Audit Partner
Carbone's director compensation follows the terms in the proxy statement filed February 19, 2025
CooperCompanies reported fiscal first-quarter 2025 results for the period ended January 31, 2025, with revenue up 4% to $964.7 million and GAAP diluted EPS of $0.52, compared with $0.41 a year earlier. The company also raised the low end of its fiscal 2025 non-GAAP diluted EPS guidance to $3.94 to $4.02, from $3.92 to $4.02, which gives shareholders a higher expected earnings floor for the year.
Q1 revenue of $964.7 million, up 4% from $931.6 million a year earlier; up 5% in constant currency and organically
GAAP diluted EPS of $0.52 vs. $0.41; non-GAAP diluted EPS of $0.92 vs. $0.85
Fiscal 2025 non-GAAP diluted EPS guidance raised to $3.94 to $4.02 from $3.92 to $4.02
Fiscal 2025 total revenue guidance of $4,080 million to $4,158 million, with organic growth of 6% to 8%
Cooper Companies said director William A. Kozy informed the board on January 31, 2025 that he will retire as a director at the company's next annual meeting of stockholders in April 2025. The filing states there are no disagreements between Mr. Kozy and the company on its operations, policies or practices.
William A. Kozy informed the board on January 31, 2025 of his retirement decision.
Retirement is effective on the date of the April 2025 annual meeting of stockholders.
The filing states there are no disagreements between Mr. Kozy and the company.
Cooper Companies reported fiscal fourth-quarter 2024 revenue of $1,018.4 million, up 10%, and GAAP diluted EPS of $0.58, up 38%, with fiscal 2024 revenue of $3.9 billion and GAAP diluted EPS of $1.96. The company also issued its first fiscal 2025 financial guidance, projecting non-GAAP diluted EPS of $3.92 to $4.02 against fiscal 2024 non-GAAP EPS of $3.69.
Q4 2024 revenue $1,018.4 million, up 10% (up 7% organically); CooperVision $676.4 million, CooperSurgical $342.0 million
Q4 2024 GAAP diluted EPS $0.58, up 38%; non-GAAP diluted EPS $1.04, up 19%
Fiscal 2024 revenue $3,895.4 million, up 8%; GAAP diluted EPS $1.96; non-GAAP diluted EPS $3.69, up 15%
Fiscal 2025 guidance: total revenue $4,080 to $4,158 million; non-GAAP diluted EPS $3.92 to $4.02
CooperCompanies reported fiscal third-quarter 2024 results for the quarter ended July 31, 2024, with revenue up 8% year over year and GAAP diluted EPS up 22%. The company also raised its fiscal 2024 financial guidance, including non-GAAP diluted EPS of $3.64 to $3.67, which gives shareholders a higher outlook for the year.
Quarterly revenue of $1,002.8 million, up 8% year over year; CooperVision rose 7% to $675.6 million and CooperSurgical rose 9% to $327.2 million.
GAAP diluted EPS of $0.52, up $0.09 or 22%; non-GAAP diluted EPS of $0.96, up 14%.
Fiscal 2024 guidance raised: total revenue of $3,892 to $3,913 million and non-GAAP diluted EPS of $3.64 to $3.67.
GAAP operating margin of 19% versus 16% a year earlier; free cash flow of $118.5 million.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Cooper Companies (The) filing is on SEC EDGAR ↗. 8-K briefs of other companies →